Skip to main content

Table 1 Demographic characteristics of participants undergoing MRI and PET

From: Microglial activation, tau and amyloid deposition in TREM2 p.R47H carriers and mild cognitive impairment patients: a multi-modal/multi-tracer PET/MRI imaging study with influenza vaccine immune challenge

 

Imaging controls

(n = 8)

MCI

(n = 8)

TREM2 p.R47H

(n = 8)

Age (years)

(median + IQR)

45.5

(43.3–48.8)

70.7

(64.0–75.8)

62.3

(60.7–67.7)a,b

Sex

(male/female)

8/0

6/2

5/3a

TSPO genotype

(MAB/HAB)

2/6

5/3

4/4

APOEε4

(carrier/non-carrier)

–

4/4

2/6

Amyloid status

(positive/negative)

–

2/6

1/7

WM—hypointensity volume (cm3) (median + IQR)

1.0

(0.9–1.6)

1.9

(1.4–4.6)

1.5

(0.9–2.0)

  1. APOEε4 carrier refers to the number with ≥ 1 ε4 allele
  2. Positive amyloid status refers to having a summary cortical SUVR of > 1.11 on amyloid PET
  3. HAB high-affinity binder, IQR  interquartile range, MAB  mixed-affinity binder, MCI  mild cognitive impairment, TSPO  translocator protein, WM  white matter
  4. aTREM2 p.R47H carrier significant versus controls; P < 0.05
  5. bTREM2 p.R47H carrier significant versus MCI group; P < 0.05